Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, Garrison L Jr, Donnell D.

Value Health. 2019 Feb;22(2):194-202. doi: 10.1016/j.jval.2018.09.001. Epub 2018 Nov 2.

PMID:
30711064
2.

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease.

Zimmermann M, Lubinga SJ, Banken R, Rind D, Cramer G, Synnott PG, Chapman RH, Khan S, Carlson J.

Value Health. 2019 Feb;22(2):161-167. doi: 10.1016/j.jval.2018.09.2841. Epub 2018 Oct 25.

PMID:
30711060
3.

The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks.

Agboola F, Lubinga S, Carlson J, Lin GA, Dreitlein WB, Pearson SD.

J Manag Care Spec Pharm. 2019 Feb;25(2):143-148. doi: 10.18553/jmcp.2019.25.2.143.

4.

How can clinical researchers quantify the value of their proposed comparative research?

Basu A, Veenstra DL, Carlson JJ, Wang WJ, Branch K, Probstfield J.

Am Heart J. 2019 Mar;209:116-125. doi: 10.1016/j.ahj.2018.12.003. Epub 2018 Dec 8. No abstract available.

PMID:
30638543
5.

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, Chapman RH, Kumar V, Carlson JJ.

CNS Drugs. 2018 Dec;32(12):1145-1157. doi: 10.1007/s40263-018-0566-9.

PMID:
30141001
6.

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.

Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD.

Cancer Med. 2018 Sep;7(9):4251-4260. doi: 10.1002/cam4.1657. Epub 2018 Jul 20.

7.

Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.

Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J.

J Drugs Dermatol. 2018 Jul 1;17(7):750-756.

PMID:
30005097
8.

The Authors Respond.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA.

J Manag Care Spec Pharm. 2018 Jul;24(7):712-713. doi: 10.18553/jmcp.2018.24.7.712.

9.

Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

Grewal S, Ramsey S, Balu S, Carlson JJ.

Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):447-454. doi: 10.1080/14737167.2018.1476142. Epub 2018 May 18.

PMID:
29757040
10.

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.

Carlson JJ, Suh K, Orfanos P, Wong W.

Pharmacoeconomics. 2018 Apr;36(4):495-504. doi: 10.1007/s40273-018-0625-6.

PMID:
29488070
11.

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA.

J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. doi: 10.18553/jmcp.2018.24.1.29.

12.

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.

Yeung K, Li M, Carlson JJ.

J Manag Care Spec Pharm. 2017 Oct;23(10):1010-1015. doi: 10.18553/jmcp.2017.23.10.1010.

13.

Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.

Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ.

J Manag Care Spec Pharm. 2017 Oct;23(10):1084-1090. doi: 10.18553/jmcp.2017.23.10.1084.

14.

Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis.

Canestaro WJ, Hendrix N, Bansal A, Sullivan SD, Devine EB, Carlson JJ.

J Clin Epidemiol. 2017 Dec;92:58-68. doi: 10.1016/j.jclinepi.2017.08.004. Epub 2017 Aug 31. Review.

PMID:
28842289
15.

Performance-Based Risk-Sharing Arrangements: An Updated International Review.

Carlson JJ, Chen S, Garrison LP Jr.

Pharmacoeconomics. 2017 Oct;35(10):1063-1072. doi: 10.1007/s40273-017-0535-z. Review.

PMID:
28695544
16.

The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.

Adamson BJS, Carlson JJ, Kublin JG, Garrison LP.

Vaccines (Basel). 2017 May 24;5(2). pii: E13. doi: 10.3390/vaccines5020013.

17.

Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.

Yu JS, Hansen RN, Valderrama A, Carlson JJ.

Leuk Lymphoma. 2016 Nov;57(11):2636-43. doi: 10.3109/10428194.2016.1161187. Epub 2016 Apr 14.

PMID:
27077242
18.

Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.

Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ.

Med Decis Making. 2016 Jul;36(5):641-51. doi: 10.1177/0272989X16636847. Epub 2016 Mar 24.

19.

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.

Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL.

J Natl Cancer Inst. 2015 Dec 29;108(2). pii: djv324. doi: 10.1093/jnci/djv324. Print 2016 Feb.

20.

Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.

Garrison LP Jr, Carlson JJ, Bajaj PS, Towse A, Neumann PJ, Sullivan SD, Westrich K, Dubois RW.

Am J Manag Care. 2015 Sep;21(9):632-40.

Supplemental Content

Loading ...
Support Center